Education
About Us
Working with TipRanks
Follow Us
RemeGen Co. Ltd. Class H (HK:9995)
:9995
9995 Stock Chart & Stats
HK$81.90
-HK$0.38(-3.04%)
At close: 4:00 PM EST
HK$81.90
-HK$0.38(-3.04%)
Day’s Range― - ―
52-Week RangeHK$14.96 - HK$126.60
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.34M
Market Cap
HK$57.17B
Enterprise ValueHK$56.06B
Total Cash (Recent Filing)HK$1.18B
Total Debt (Recent Filing)HK$2.18B
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)3.66
Price to Sales (P/S)4.24
P/FCF Ratio-5.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$102.70Price Target Upside25.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthAn 83.24% gross margin indicates strong product pricing and efficient biologics manufacturing economics. This durable margin provides a structural cushion to absorb SG&A and R&D, enabling a clearer path to operating profitability if the company achieves scale and cost control over coming quarters.
Revenue Growth TrendSustained revenue growth of 10.01% TTM demonstrates commercial traction for approved therapies and expanding market adoption. Continued top-line expansion supports fixed-cost absorption and scale benefits, improving the odds of durable margin improvement and self‑funding capacity over the next several quarters.
Partnerships And DistributionStructural collaborations broaden distribution, provide milestone/royalty streams, and accelerate access to international markets. These partnerships diversify revenue sources, reduce single-market commercialization risk, and strengthen long-term go-to-market capabilities beyond transient sales cycles.
Bears Say
Cash Flow DeteriorationA -63.15% decline in free cash flow and negative operating cash flow reveal the business consumes cash despite revenue gains. This structural cash burn heightens financing risk, may force dilution or spending cuts, and constrains investment in R&D and commercial expansion over the medium term.
Persistent UnprofitabilityOngoing negative net income and EBIT margins, alongside a negative ROE, indicate the company has yet to convert high gross margins into operating profit. Persistent unprofitability erodes equity, limits self‑funding of growth, and necessitates sustained margin improvement or recurring external capital raises.
Elevated Leverage RiskDebt-to-equity near 0.94, while improved, still represents meaningful leverage. Combined with negative cash flow and losses, this level raises refinancing and interest burden risk, reducing financial flexibility to fund pipeline development or scale commercialization without additional external financing.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$14.96 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$57.17B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Mar 28, 2026 which is in 34 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Oct 30, 2025. The company reported -HK$0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.204.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of -HK$0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.263%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
-39.64%
Trailing 12-Months
Asset Growth
3.65%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$102.70
▲(25.40% Upside)
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---